Tyrosine phosphatase SHP2 aggravates tumor progression and glycolysis by dephosphorylating PKM2 in gastric cancer

Abstract

Gastric cancer (GC) is among the most lethal human malignancies, yet it remains hampered by challenges in fronter of molecular-guided targeted therapy to direct clinical treatment strategies. The protein tyrosine phosphatase Src homology 2 domain-containing phosphatase 2 (SHP2) is involved in the malignant progression of GC. However, the detailed mechanisms of the posttranslational modifications of SHP2 remain poorly understood. Herein, we demonstrated that an allosteric SHP2 inhibitor, SHP099, was able to block tumor proliferation and migration of GC by dephosphorylating the pyruvate kinase M2 type (PKM2) protein. Mechanistically, we found that PKM2 is a bona fide target of SHP2. The dephosphorylation and activation of PKM2 by SHP2 are necessary to exacerbate tumor progression and GC glycolysis. Moreover, we demonstrated a strong correlation between the phosphorylation level of PKM2 and adenosine 5‘-monophosphate (AMP)-activated protein kinase (AMPK) in GC cells. Notably, the low phosphorylation expression of AMPK was negatively correlated with activated SHP2. Besides, we proved that cisplatin could activate SHP2 and SHP099 increased sensitivity to cisplatin in GC. Taken together, our results provide evidence that the SHP2/PKM2/AMPK axis exerts a key role in GC progression and glycolysis and could be a viable therapeutic approach for the therapy of GC.

Keywords

gastric cancer / glycolysis / PKM2 / posttranslational modifications / SHP2

References

1	H Sung, J Ferlay, RL Siegel, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
2	M Arnold, JY Park, MC Camargo, N Lunet, D Forman, I Soerjomataram. Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035. Gut. 2020;69(5):823-829.
3	EV Heer, AS Harper, H Sung, A Jemal, MM Fidler-Benaoudia. Emerging cancer incidence trends in Canada: the growing burden of young adult cancers. Cancer. 2020;126(20):4553-4562.
4	BT Seet, I Dikic, MM Zhou, T Pawson. Reading protein modifications with interaction domains. Nat Rev Mol Cell Biol. 2006;7(7):473-483.
5	AV Leopold, KG Chernov, VV Verkhusha. Optogenetically controlled protein kinases for regulation of cellular signaling. Chem Soc Rev. 2018;47(7):2454-2484.
6	S Pan, R Chen. Pathological implication of protein post-translational modifications in cancer. Mol Aspects Med. 2022;86:101097.
7	G Zhu, L Jin, W Sun, S Wang, N Liu. Proteomics of post-translational modifications in colorectal cancer: discovery of new biomarkers. Biochim Biophys Acta Rev Cancer. 2022;1877(4):188735.
8	J Liu, Z Liu, W Yan, et al. ENKUR recruits FBXW7 to ubiquitinate and degrade MYH9 and further suppress MYH9-induced deubiquitination of β-catenin to block gastric cancer metastasis. MedComm. 2022;3(4):e185.
9	RJ Nichols, F Haderk, C Stahlhut, et al. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nat Cell Biol. 2018;20(9):1064-1073.
10	JR LaRochelle, M Fodor, V Vemulapalli, et al. Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition. Nat Commun. 2018;9(1):4508.
11	Y Liu, X Yang, Y Wang, et al. Targeting SHP2 as a therapeutic strategy for inflammatory diseases. Eur J Med Chem. 2021;214:113264.
12	C Hall, H Yu, E Choi. Insulin receptor endocytosis in the pathophysiology of insulin resistance. Exp Mol Med. 2020;52(6):911-920.
13	D Shen, W Chen, J Zhu, et al. Therapeutic potential of targeting SHP2 in human developmental disorders and cancers. Eur J Med Chem. 2020;190:112117.
14	S Imai, T Ooki, N Murata-Kamiya, et al. Helicobacter pylori CagA elicits BRCAness to induce genome instability that may underlie bacterial gastric carcinogenesis. Cell Host Microbe. 2021;29(6):941-958.
15	A Takahashi-Kanemitsu, CT Knight, M Hatakeyama. Molecular anatomy and pathogenic actions of Helicobacter pylori CagA that underpin gastric carcinogenesis. Cell Mol Immunol. 2020;17(1):50-63.
16	H Higashi, R Tsutsumi, S Muto, et al. SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science. 2002;295(5555):683-686.
17	GS Wong, J Zhou, JB Liu, et al. Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med. 2018;24(7):968-977.
18	J Wu, H Zhang, G Zhao, R Wang. Allosteric inhibitors of SHP2: an updated patent review (2015–2020). Curr Med Chem. 2021;28(19):3825-3842.
19	X Yuan, H Bu, J Zhou, CY Yang, H Zhang. Recent advances of SHP2 inhibitors in cancer therapy: current development and clinical application. J Med Chem. 2020;63(20):11368-11396.
20	P Wang, C Sun, T Zhu, Y Xu. Structural insight into mechanisms for dynamic regulation of PKM2. Protein Cell. 2015;6(4):275-287.
21	EK Wiese, T Hitosugi. Tyrosine kinase signaling in cancer metabolism: pKM2 paradox in the Warburg effect. Front Cell Dev Biol. 2018;6:79.
22	Z Chen, Z Wang, W Guo, et al. TRIM35 interacts with pyruvate kinase isoform M2 to suppress the Warburg effect and tumorigenicity in hepatocellular carcinoma. Oncogene. 2015;34(30):3946-3956.
23	S Yang, LH Long, D Li, et al. β-Guanidinopropionic acid extends the lifespan of Drosophila melanogaster via an AMP-activated protein kinase-dependent increase in autophagy. Aging Cell. 2015;14(6):1024-1033.
24	M Li, L Zhao, J Liu, et al. Multi-mechanisms are involved in reactive oxygen species regulation of mTORC1 signaling. Cell Signal. 2010;22(10):1469-1476.
25	EP Rogakou, DR Pilch, AH Orr, VS Ivanova, WM Bonner. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998;273(10):5858-5868.
26	RE Sexton, MN Al Hallak, M Diab, AS Azmi. Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer Metastasis Rev. 2020;39(4):1179-1203.
27	M Sasako. Progress in the treatment of gastric cancer in Japan over the last 50 years. Ann Gastroenterol Surg. 2020;4(1):21-29.
28	J Machlowska, J Baj, M Sitarz, R Maciejewski, R Sitarz. Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci. 2020;21(11).
29	Z Du, CM Lovly. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018;17(1):58.
30	A Ostman, C Hellberg, FD B?hmer. Protein-tyrosine phosphatases and cancer. Nat Rev Cancer. 2006;6(4):307-320.
31	LR Bollu, A Mazumdar, MI Savage, PH Brown. Molecular pathways: targeting protein tyrosine phosphatases in cancer. 2017:2136-2142.
32	GS Feng, CC Hui, T Pawson. SH2-containing phosphotyrosine phosphatase as a target of protein-tyrosine kinases. Science. 1993;259(5101):1607-1611.
33	C Fedele, S Li, KW Teng, et al. SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling. J Exp Med. 2021;218(1).
34	L Dardaei, HQ Wang, M Singh, et al. SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. Nat Med. 2018;24(4):512-517.
35	H Chen, S Libring, KV Ruddraraju, et al. SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer. Oncogene. 2020;39(49):7166-7180.
36	Z Song, M Wang, Y Ge, et al. Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies. Acta Pharm Sin B. 2021;11(1):13-29.
37	Y Song, M Zhao, H Zhang, B Yu. Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials. Pharmacol Ther. 2021:107966.
38	J Xie, X Si, S Gu, et al. Allosteric inhibitors of SHP2 with therapeutic potential for cancer treatment. J Med Chem. 2017;60(24):10205-10219.
39	T Hayashi, M Senda, N Suzuki, et al. Differential mechanisms for SHP2 binding and activation are exploited by geographically distinct Helicobacter pylori CagA oncoproteins. Cell Rep. 2017;20(12):2876-2890.
40	HR Christofk, MG Vander Heiden, N Wu, JM Asara, LC Cantley. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature. 2008;452(7184):181-186.
41	Y Pan, W Wang, S Huang, et al. Beta-elemene inhibits breast cancer metastasis through blocking pyruvate kinase M2 dimerization and nuclear translocation. J Cell Mol Med. 2019;23(10):6846-6858.
42	J Xie, C Dai, X Hu. Evidence that does not support pyruvate kinase M2 (PKM2)-catalyzed reaction as a rate-limiting step in cancer cell glycolysis. J Biol Chem. 2016;291(17):8987-8999.
43	PS Ward, CB Thompson. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012;21(3):297-308.
44	D Anastasiou, G Poulogiannis, JM Asara, et al. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science. 2011;334(6060):1278-1283.
45	T Hitosugi, S Kang, MG Vander Heiden, et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal. 2009;2(97):ra73.
46	Z Zhou, M Li, L Zhang, et al. Oncogenic kinase-induced PKM2 tyrosine 105 phosphorylation converts nononcogenic PKM2 to a tumor promoter and induces cancer stem-like cells. Cancer Res. 2018;78(9):2248-2261.
47	Q Xu, N Wu, X Li, et al. Inhibition of PTP1B blocks pancreatic cancer progression by targeting the PKM2/AMPK/mTOC1 pathway. Cell Death Dis. 2019;10(12):874.
48	C Dominguez, R Boelens, AM Bonvin. HADDOCK: a protein-protein docking approach based on biochemical or biophysical information. J Am Chem Soc. 2003;125(7):1731-1737.